Alpha DNA Investment Management LLC Invests $441,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Alpha DNA Investment Management LLC purchased a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,663 shares of the company's stock, valued at approximately $441,000.

Several other institutional investors have also recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Mirum Pharmaceuticals by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 943,344 shares of the company's stock worth $39,016,000 after acquiring an additional 7,147 shares in the last quarter. Clearbridge Investments LLC boosted its position in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Clearbridge Investments LLC now owns 907,317 shares of the company's stock worth $37,518,000 after purchasing an additional 18,217 shares during the period. Lord Abbett & CO. LLC purchased a new stake in shares of Mirum Pharmaceuticals in the third quarter worth $28,913,000. Loomis Sayles & Co. L P raised its position in shares of Mirum Pharmaceuticals by 15.8% during the 4th quarter. Loomis Sayles & Co. L P now owns 578,024 shares of the company's stock valued at $23,901,000 after purchasing an additional 78,708 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Mirum Pharmaceuticals by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 332,639 shares of the company's stock valued at $13,755,000 after buying an additional 4,478 shares in the last quarter.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84. Following the completion of the transaction, the senior vice president now directly owns 3,524 shares of the company's stock, valued at $168,870.08. The trade was a 20.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This represents a 16.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,473 shares of company stock valued at $5,249,134. Insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock traded up $0.88 during midday trading on Thursday, reaching $40.50. 70,122 shares of the stock traded hands, compared to its average volume of 522,343. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The stock's fifty day moving average is $44.55 and its 200-day moving average is $43.94. The stock has a market cap of $2.00 billion, a P/E ratio of -20.05 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). The business had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.